Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dynavax Technologies Corporation
Ragweed allergy is the most common seasonal allergy in North America. Allergen immunotherapy is a therapeutic option for patients who have allergy symptoms that cannot be adequately controlled by avoidance of the allergen or medication. It may also be appropriate for those who cannot tolerate their medications due to side effects or have difficulties with medication compliance. This study compares the safety and efficacy of two different dosing regimens of TOLAMBA™ with placebo in reducing the symptoms of ragweed-allergic adults over two consecutive ragweed pollen seasons.
Comparison(s): Subject-rated allergy symptoms of subjects treated with TOLAMBA™ dose-intense regimen or TOLAMBA™ lower-dose regimen, compared with subjects treated with placebo.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a history of ragweed allergic rhinitis (hayfever) during at least the last 2 consecutive seasons that has required treatment with antihistamines, decongestants and/or nasal steroids, but where symptom relief has been incomplete
Is willing to stay in their ragweed area during the historical peak period of the local ragweed season, and willing to travel for no more than 2 weeks (cumulative time) outside of their ragweed area during the entire season
You may not be if
Has had any hospital admissions for asthma
Has smoked within the past year, or has a ≥10-pack per year smoking history
Has had any previous immunotherapy with ragweed pollen extract, or was in a previous clinical trial with TOLAMBA™
Has used Xolair within the past 12 months
Has a history of anaphylaxis
Clareo Health | Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
